Nuvation Bio (NUVB) Long-Term Deferred Tax (2020 - 2025)
Nuvation Bio (NUVB) posted quarterly Long-Term Deferred Tax of $245.0 million for Q4 2025, up 127.46% year-over-year from $107.7 million in Q4 2024, and up 127.46% quarter-over-quarter from $107.7 million in Q4 2024.
Powered by 
Analysis
Nuvation Bio (NUVB) Long-Term Deferred Tax (2020 - 2025) Analysis & Trends
Nuvation Bio (NUVB) has reported Long-Term Deferred Tax for 3 consecutive years, with $245.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Deferred Tax rose 127.46% year-over-year to $245.0 million; the TTM figure through Dec 2025 stood at $245.0 million (up 127.46% YoY), while the FY2025 annual figure was $245.0 million, up 127.46% from the prior year.
- Long-Term Deferred Tax improved to $245.0 million in Q4 2025 per NUVB's latest filing, from $107.7 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $245.0 million in Q4 2025 and bottomed at $107.7 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Nuvation Bio | 2.38 Bn | 2.38 Bn | 30.78 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 244.97 Mn |
| Dec 31, 2024 | 242.59 Mn |
| Dec 31, 2023 | 101.41 Mn |
| Sep 30, 2020 | 154,000.00 |